125 related articles for article (PubMed ID: 34878770)
1. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.
Luxenburger A; Bougen-Zhukov N; Fraser MG; Beetham H; Harris LD; Schmidt D; Cameron SA; Guilford PJ; Evans GB
J Med Chem; 2021 Dec; 64(24):18114-18142. PubMed ID: 34878770
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
Godwin TD; Kelly ST; Brew TP; Bougen-Zhukov NM; Single AB; Chen A; Stylianou CE; Harris LD; Currie SK; Telford BJ; Beetham HG; Evans GB; Black MA; Guilford PJ
Gastric Cancer; 2019 Mar; 22(2):273-286. PubMed ID: 30066183
[TBL] [Abstract][Full Text] [Related]
3. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
Beetham H; Chen A; Telford BJ; Single A; Jarman KE; Lackovic K; Luxenburger A; Guilford P
Sci Rep; 2019 Aug; 9(1):12511. PubMed ID: 31467357
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
Telford BJ; Chen A; Beetham H; Frick J; Brew TP; Gould CM; Single A; Godwin T; Simpson KJ; Guilford P
Mol Cancer Ther; 2015 May; 14(5):1213-23. PubMed ID: 25777964
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Chen I; Mathews-Greiner L; Li D; Abisoye-Ogunniyan A; Ray S; Bian Y; Shukla V; Zhang X; Guha R; Thomas C; Gryder B; Zacharia A; Beane JD; Ravichandran S; Ferrer M; Rudloff U
J Transl Med; 2017 May; 15(1):92. PubMed ID: 28460635
[TBL] [Abstract][Full Text] [Related]
6. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.
Bougen-Zhukov N; Nouri Y; Godwin T; Taylor M; Hakkaart C; Single A; Brew T; Permina E; Chen A; Black MA; Guilford P
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540244
[TBL] [Abstract][Full Text] [Related]
7. THE STUDY OF THE EXPRESSION OF CDH1, KI67, P53 AND HER2 IN DIFFUSE GASTRIC CARCINOMA.
Muzashvili T; Tutisani A; Chabradze G; Beridze N; Museridze N
Georgian Med News; 2020 Feb; (299):147-150. PubMed ID: 32242863
[TBL] [Abstract][Full Text] [Related]
8. Overview on new progress of hereditary diffuse gastric cancer with
Hu MN; Hu SH; Zhang XW; Xiong SM; Deng H
Tumori; 2020 Oct; 106(5):346-355. PubMed ID: 32811340
[TBL] [Abstract][Full Text] [Related]
9. Clinical spectrum and pleiotropic nature of
Figueiredo J; Melo S; Carneiro P; Moreira AM; Fernandes MS; Ribeiro AS; Guilford P; Paredes J; Seruca R
J Med Genet; 2019 Apr; 56(4):199-208. PubMed ID: 30661051
[No Abstract] [Full Text] [Related]
10. Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking.
Brew T; Bougen-Zhukov N; Mitchell W; Decourtye L; Schulpen E; Nouri Y; Godwin T; Guilford P
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008266
[TBL] [Abstract][Full Text] [Related]
11. A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach.
Caggiari L; Miolo G; Canzonieri V; De Zorzi M; Alessandrini L; Corona G; Cannizzaro R; Santeufemia DA; Cossu A; Buonadonna A; De Re V
Cancer Biol Ther; 2018 Apr; 19(4):254-259. PubMed ID: 29131691
[TBL] [Abstract][Full Text] [Related]
12. Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer.
Moslim MA; Heald B; Tu C; Burke CA; Walsh RM
Surgery; 2018 Oct; 164(4):754-759. PubMed ID: 30145018
[TBL] [Abstract][Full Text] [Related]
13. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.
Kaurah P; MacMillan A; Boyd N; Senz J; De Luca A; Chun N; Suriano G; Zaor S; Van Manen L; Gilpin C; Nikkel S; Connolly-Wilson M; Weissman S; Rubinstein WS; Sebold C; Greenstein R; Stroop J; Yim D; Panzini B; McKinnon W; Greenblatt M; Wirtzfeld D; Fontaine D; Coit D; Yoon S; Chung D; Lauwers G; Pizzuti A; Vaccaro C; Redal MA; Oliveira C; Tischkowitz M; Olschwang S; Gallinger S; Lynch H; Green J; Ford J; Pharoah P; Fernandez B; Huntsman D
JAMA; 2007 Jun; 297(21):2360-72. PubMed ID: 17545690
[TBL] [Abstract][Full Text] [Related]
14. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer.
Bustos-Carpinteyro AR; Oliveira C; Sousa A; Oliveira P; Pinheiro H; Carvalho J; Magaña-Torres MT; Flores-Miramontes MG; Aguilar-Lemarroy A; Jave-Suárez LF; Peregrina-Sandoval J; Cruz-Ramos JA; Sánchez-López JY
BMC Cancer; 2019 Jan; 19(1):69. PubMed ID: 30642281
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
[TBL] [Abstract][Full Text] [Related]
16. Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature.
Obermair F; Rammer M; Burghofer J; Malli T; Schossig A; Wimmer K; Kranewitter W; Mayrbaeurl B; Duba HC; Webersinke G
Fam Cancer; 2019 Apr; 18(2):253-260. PubMed ID: 30306390
[TBL] [Abstract][Full Text] [Related]
17. E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors.
Decourtye-Espiard L; Bougen-Zhukov N; Godwin T; Brew T; Schulpen E; Black MA; Guilford P
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008338
[TBL] [Abstract][Full Text] [Related]
18. Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC).
Lo W; Zhu B; Sabesan A; Wu HH; Powers A; Sorber RA; Ravichandran S; Chen I; McDuffie LA; Quadri HS; Beane JD; Calzone K; Miettinen MM; Hewitt SM; Koh C; Heller T; Wacholder S; Rudloff U
J Med Genet; 2019 Jun; 56(6):370-379. PubMed ID: 30745422
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study.
Bardram L; Hansen TV; Gerdes AM; Timshel S; Friis-Hansen L; Federspiel B
Fam Cancer; 2014 Jun; 13(2):231-42. PubMed ID: 24389957
[TBL] [Abstract][Full Text] [Related]
20. Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori.
Hakkaart C; Ellison-Loschmann L; Day R; Sporle A; Koea J; Harawira P; Cheng S; Gray M; Whaanga T; Pearce N; Guilford P
Fam Cancer; 2019 Jan; 18(1):83-90. PubMed ID: 29589180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
